Teriparitide (TPD) is a novel anabolic agent that stimulates bone formation. TPD reduces risk of vertebral and nonvertebral fracture. Due to its positive effects on bone formation, many new uses of TPD are being explored. It has been studied and approved for glucocorticoid-induced osteoporosis. Many questions about the use of TPD remain including use of follow-up therapy, combination therapy, sequential therapy, and its potential role in fracture healing and treatment of back pain related to osteoporosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rdc.2011.08.002 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!